The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited GNI armamentarium. Despite the launch of novel antibiotics, such as Avycaz / Zavicefta, Zerbaxa, Recarbrio, and Fetroja / Fetcroja, unmet need remains for additional effective treatment options with efficacy in patients with drug-resistant infections, which are associated with high rates of mortality. Although the market is heavily genericized and cost-containment measures have limited commercial success of emerging therapies, innovative approaches like value based pricing (VBP) and de-linked reimbursement models promise to encourage and support future antibiotics' development.
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary Research: More than 20 country-specific interviews with thought-leading infectious disease specialists. Supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed events of GNIs segmented by key indications (nosocomial pneumonia, complicated skin and skin structure infections / surgical site infections, bloodstream infections, complicated intra-abdominal infections, urinary tract infections), pathogens (E.coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2030, segmented by brands / generics, geography, and five key indications.
Emerging Therapies: Phase III/PR: 7 drugs; Phase I/Phase II: 12 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.